In the last decade, microRNAs (miRs) have been described as biomarkers and therapeutic agents. Based on this finding, our aim here is to know if (1) miRNA-370-3p can be used as a biomarker associated with a favorable survival and if (2) miRNA-370-3p can be used as a therapeutic tool that increases the efficiency of standard anti-GBM treatment. A first approach using the data available on the “Prognostic miRNA Database” indicated that the expression level of miRNA-370-3p in GBM (T-miR-370-3p) is not associated with a prognosis value for survival. A second approach quantifying the expression level of cell-free circulating miRNA-370-3p (cfc-miR-370-3p) also indicated that cfc-miR-370-3p is not associated with a prognosis value for survival. To investigate whether miR-370-3p can be used in vivo to increase the anti-GBM effect of TMZ, we then used the model of LN18-induced GBMs in mice. Our data indicated that the miRNA-370-3p/TMZ treatment was two times more efficient than the TMZ treatment for decreasing the tumor volume. In addition, our study correlated the decrease of tumor volume induced by the miRNA-370-3p/TMZ treatment with the decrease in FOXM1 and MGMT (i.e., two targets of miR-370-3p).

Our data thus support the idea that miR-370-3p could be used as therapeutic tool for anti-glioblastoma therapy, but not as a biomarker.

在过去的十年中，microRNA（miRs）被描述为生物标志物和治疗剂。基于此发现，我们的目的是了解（1）miRNA-370-3p是否可用作与良好生存相关的生物标志物，以及（2）miRNA-370-3p是否可用作增加生存率的治疗工具。标准抗GBM处理的效率。使用“预后miRNA数据库”上可用数据的第一种方法表明，GBM（T-miR-370-3p）中miRNA-370-3p的表达水平与生存的预后值无关。定量无细胞循环miRNA-370-3p（cfc-miR-370-3p）表达水平的第二种方法还表明，cfc-miR-370-3p与存活的预后值无关。调查是否可以在体内使用miR-370-3p为了增加TMZ的抗GBM作用，我们然后使用了LN18诱导的GBMs小鼠模型。我们的数据表明，miRNA-370-3p / TMZ治疗在减少肿瘤体积方面比TMZ治疗有效两倍。此外，我们的研究将miRNA-370-3p / TMZ治疗诱导的肿瘤体积减少与FOXM1和MGMT（即miR-370-3p的两个靶标）减少相关。

因此，我们的数据支持miR-370-3p可用作抗胶质母细胞瘤治疗的治疗工具，但不能用作生物标记的想法。